Get started
Author

Carlos Stecca

Observed names: C Stecca, C. Stecca, Carlos E. Stecca, Carlos Eduardo Stecca, Stecca, Carlos Eduardo
Observed institutions: University Health Network, University of Toronto, Princess Margaret Cancer Centre, AC Camargo Hospital, Hospital Universitário Evangélico de Curitiba, Instituto de Oncologia do Paraná, Ospedale San Bortolo
ORCID: 0000-0001-9103-9119
Observed ORCID: 0000-0001-9103-9119
OpenAlex ID: A5017195129
Metastatic Urothelial Cancer: a rapidly changing treatment landscape
2021 · Carlos Stecca, Osama Abdeljalil, et al. · Therapeutic Advances in Medical Oncology · 65
Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature
2021 · Carlos E. Stecca, Marie Alt, et al. · Oncology and Therapy · 53
PDF
Enfortumab Vedotin in urothelial cancer
2020 · Marie Alt, Carlos Stecca, et al. · Therapeutic Advances in Urology · 46
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes
2019 · Alexandre A. B. A. da Costa, Luisa M. do Canto, et al. · BMC Cancer · 33
PDF
Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: An updated meta-analysis of randomized controlled trials
2024 · Nicole Felix, Paula C. Nogueira, et al. · European Journal of Internal Medicine · 29
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis
2024 · I. Michelon, M. Vilbert, et al. · ESMO Open · 26
PDF
PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
2023 · Francisco Cezar Aquino de Moraes, Eric Pasqualotto, et al. · BMC Cancer · 26
PDF
The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma
2018 · Alexandre A. B. A. da Costa, Felipe D’Almeida Costa, et al. · Medical Oncology · 20
Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis
2024 · Francisco Cezar Aquino de Moraes, Caroline R. M. Pereira, et al. · Frontiers in Pharmacology · 12
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials
2024 · Francisco Cezar Aquino de Moraes, Gustavo de Oliveira Almeida, et al. · Journal of Personalized Medicine · 12
PDF
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
2024 · Isabella Michelon, Maysa Vilbert, et al. · Journal of Personalized Medicine · 10
PDF
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis
2025 · Isabella Michelon, Caio E.R. Castro, et al. · Cancer Treatment Reviews · 9
PDF
The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy
2022 · Husam A. Alqaisi, Carlos Stecca, et al. · Therapeutic Advances in Medical Oncology · 9
Effects of AKT Inhibitors for PIK3CA/AKT1/PTEN-Altered Advanced or Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials
2025 · Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, et al. · Clinical Breast Cancer · 8
Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials
2024 · Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, et al. · European Journal of Clinical Pharmacology · 8
Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
2024 · Isadora Mamede, Lorena Escalante-Romero, et al. · Clinical Genitourinary Cancer · 7
The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer
2022 · Carlos Stecca, Timur Mitin, et al. · Seminars in Radiation Oncology · 7
Survival and pulmonary function in stage IA non‐small cell lung cancer after sublobar resection versus lobectomy: An updated meta‐analysis
2024 · Isadora Mamede, Leonardo Ribeiro, et al. · Journal of Surgical Oncology · 6
PDF
Prevalence of cardiometabolic outcomes in women who underwent salpingo-oophorectomy to prevent hereditary breast and ovarian cancer: a meta-analysis
2024 · Francisco Cezar Aquino de Moraes, Lucca Dal Moro, et al. · Familial Cancer · 5
Advanced Esophageal Neoplasm with Subcutaneous Metastasis
2019 · Rivadávio A. M. de Oliveira, Tassiara da Silva, et al. · Case Reports in Oncological Medicine · 5
PDF
2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinoma
2024 · Carlos E. Stecca, Deepro Chowdhury, et al. · Canadian Urological Association Journal · 4
PDF
Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis.
2024 · Gabriela Gazzoni, João Pedro Oliveira, et al. · Journal of Clinical Oncology · 4
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)
2022 · Carlos E. Stecca, Marie Alt, et al. · Seminars in Oncology · 4
PDF
Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic
2022 · Carlos E. Stecca, Di Maria Jiang, et al. · Clinical Genitourinary Cancer · 3
Trends over time in survival in patients with urothelial carcinoma in the real-world: A multicenter analysis.
2021 · Sunil Samnani, Zachary William Neil Veitch, et al. · Journal of Clinical Oncology · 3
Works count: 64
Citation count: 445
H-index: 10
I10-index: 11
Year
Topic
Type